FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 11:46:19 2024-05-13 EDT | ||
| 0.68 EUR | -10.53% |
|
| Current month | +1.33% | ||
| 1 month | -18.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 0.68 | -10.53% | 0 |
| 24-05-10 | 0.76 | +1.33% | 0 |
| 24-05-09 | 0.75 | -6.25% | 0 |
| 24-05-08 | 0.8 | +3.90% | 0 |
| 24-05-07 | 0.77 | -16.30% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 11:46 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW13CX |
| ISIN | DE000SW13CX2 |
| Date issued | 2023-08-10 |
| Strike | 1,297 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.58 € |
|---|---|
| Lowest since issue | 0.61 € |
| Spread | 0.02 € |
| Spread % | 2.90% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat
